Impel Pharmaceuticals Inc. Common Stock
IMPL
IMPL was delisted on the 15th of December, 2023.
33 hedge funds and large institutions have $150M invested in Impel Pharmaceuticals Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KKRC
Kohlberg Kravis Roberts & Co
New York
|
+$45.4M |
| 2 |
NVPX
Norwest Venture Partners XIV
Palo Alto,
California
|
+$36.7M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
+$34.4M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
+$34.4M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
+$33M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $8K | +$10.3K | +866 | New |
|
|
AIP
27
Ameritas Investment Partners
Lincoln,
Nebraska
| $4K | +$5.04K | +422 | New |
|
28
Legal & General Group
London,
United Kingdom
| $4K | +$5.11K | +428 | New |
|
29
Bank of America
Charlotte,
North Carolina
| $3K | +$4.19K | +351 | New |
|
30
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | +$4.42K | +370 | New |
|
|
BCA
31
Berman Capital Advisors
Atlanta,
Georgia
| $3K | +$4.74K | +397 | New |
|
32
Citigroup
New York
| $2K | +$3.04K | +255 | New |
|
|
AIG
33
American International Group
New York
| $27 | +$36K | +3,016 | New |
|
IMPL Hedge Fund Activity: Q2 2021 in Review
33 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in Impel Pharmaceuticals Inc. Common Stock (IMPL) for Q2 2021, worth a combined $150M.
Buyers outnumbered sellers: 33 funds opened new IMPL positions and 0 closed out — a net gain of 33 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kohlberg Kravis Roberts & Co, opening a new position worth an estimated $45.4M.
- 33 institutional investors held Impel Pharmaceuticals Inc. Common Stock (IMPL) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $150M of Impel Pharmaceuticals Inc. Common Stock stock for Q2 2021.
- 33 funds opened new Impel Pharmaceuticals Inc. Common Stock positions in Q2 2021 and 0 closed out, a net change of +33 holders.
- The largest Impel Pharmaceuticals Inc. Common Stock buyer in Q2 2021 was Kohlberg Kravis Roberts & Co, an estimated $45.4M added.
Based on aggregated 13F filings for Q2 2021.